Therapeutic Modality: Small molecule
Mechanism of Action: Undisclosed
Rallybio has formed a joint venture with Exscientia Ltd., a world-leading PharmaTech innovator at the forefront of Artificial Intelligence (AI)/Machine Learning (ML)-driven drug discovery. This collaboration combines Exscientia’s Centaur chemist drug discovery platform with Rallybio’s expertise in rare disease drug development, with the goal of accelerating the discovery of small molecule drug therapeutics for undisclosed rare diseases. The first of these programs is targeting a rare metabolic disease.